Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin vs Cloxacillin for MSSA Bacteremia
NCT03248063Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2018
- Primary completion
- Feb 2024
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of cefazolin in Staphylococcus aureus bacteremia (SAB), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2018; status: completed.
02
Drugs
cefazolin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT03248063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248063.